Biopol
 
IDIBELL Researchers discover why tumour cells change their appearance

IDIBELL Researchers discover why tumour cells change their appearance

15/09/2011

If environmental conditions of tumors are changed, the process reverses

The study is led by Manel Esteller

Like snakes, tumour cells shed their skin. Cancer is not a static disease but during its development the disease accumulates changes to evade natural defences adapting to new environmental circumstances, protecting against chemotherapy and radiotherapy and invading neighbouring organs, eventually causing metastasis.

Until now little was known about the mechanisms involved in these changing processes in a tumour. There is a particularly intriguing way in which a tumour that initially presents a solid state, attached to nearby cells (epithelial), afterwards becomes a semiliquid mass, detached from tissues and more flexible (mesenchymal).

The team led by Manel Esteller, director of the Cancer Epigenetics and Biology Program at the Bellvitge Biomedical Research Institute (IDIBELL), professor of Genetics at the University of Barcelona and ICREA researcher, has identified a mechanism that explains this change. Tumours “shed their skin” because some molecular switches called microRNAs -responsible for maintaining epithelial appearance of cells- turn off. The finding has been published this week in the online version of the international scientific journal Oncogene, Nature group.

“We have discovered that some microRNAs, a group called microRNA-200S, undergoes a chemical inactivation and inhibit their expression. When these cellular appearance drivers are not present, tumour cells change, stretch, stop their inhibition and thus the tumour progresses”, explains Dr. Esteller, adding that “the results from research show that this is a very dynamic process.”

Change involves from the appearance of the tumour to the onset of metastasis, but if we change the environmental circumstances that influence these cells, the process reverses. Dr Esteller compares the process “with a small planet in Darwinian evolution but in an expedited manner.”

The study was conducted mainly in breast and colon tumours. Besides serving to better understand the disease, the results are important because they predict that external intervention is possible in the process. In this sense, drug treatments can reverse the process and move from a highly evolved tumour form to a more primitive form, which would be associated with a slower progression of the disease.

 


 

More news

Collaboration between Biopol’H and Valles Technology Park promotes the exchange of supplies and demands between companies and organizations

Collaboration between Biopol’H and Valles Technology Park promotes the exchange of supplies and demands between companies and organizations

04/05/2012

Biopol’H and the Valles Technology Park have signed a collaboration agreement.   

Biopol’H and Orbital 40: two Science and Technology Parks united in the promotion of excellence and innovation

Biopol’H and Orbital 40: two Science and Technology Parks united in the promotion of excellence and innovation

02/05/2012

A collaboration to stimulate the Catalan business network and create an axis between L’Hospitalet and Terrassa   

Biopol'H and PIMEC allied to work together in L'Hospitalet and Baix Llobregat

Biopol'H and PIMEC allied to work together in L'Hospitalet and Baix Llobregat

23/04/2012

The portfolio of services of the hub of innovation is expanded with the new companies attached to Biopol’H.   

ICO and IDIBELL organizations receive 1 million euros with the announcement of Science and Technology Parks

ICO and IDIBELL organizations receive 1 million euros with the announcement of Science and Technology Parks

22/04/2012

Through the subprogramme for Science and Technology Parks, Innplanta 2011, the Ministry of Economy and Competitiveness has decided to award two  

Biopol'H and the Catalan Association of Biotechnologists collaborate to strengthen synergies between researchers and companies

Biopol'H and the Catalan Association of Biotechnologists collaborate to strengthen synergies between researchers and companies

21/04/2012

The agreement creates strong bonds between the ASBTEC (Catalan Association of Biotechnologists) – whose objective is to coordinate the group of  

 
 
Consortium: